Sol-Gel Technologies (SLGL) Shares Outstanding (2015 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Shares Outstanding (Entity) of $2.8 million for Q1 2026, up 1.84% year-over-year from $2.8 million in Q1 2025, and up 1.83% quarter-over-quarter from $2.8 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Shares Outstanding (2015 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Shares Outstanding (Entity) for 11 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1.84% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 1.84% YoY), while the FY2025 annual figure was $2.8 million, changed 0.0% from the prior year.
- Shares Outstanding (Entity) rose to $2.8 million in Q1 2026 per SLGL's latest filing, from $2.8 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $2.8 million in Q1 2026 and bottomed at $2.3 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $2.6 million across 5 years, with a median of $2.8 million in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 20.38% — and 2025, when it changed 0.0%.
- Sol-Gel Technologies' Shares Outstanding (Entity) stood at $2.3 million in 2022, then gained by 17.11% to $2.7 million in 2023, then increased by 2.84% to $2.8 million in 2024, then advanced by 0.0% to $2.8 million in 2025, then increased by 1.83% to $2.8 million in 2026.
- Business Quant data shows SLGL's Shares Outstanding (Entity) at $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Sol-Gel Technologies | 195.40 Mn | 147.47 Mn | - | 2.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.79 Mn |
| Mar 31, 2026 | 2.79 Mn |
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 2.79 Mn |
| Jun 30, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 2.31 Mn |
| Jun 30, 2023 | 2.31 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.31 Mn |
| Jun 30, 2022 | 2.31 Mn |
| Mar 31, 2022 | 2.31 Mn |
| Dec 31, 2021 | 2.31 Mn |
| Sep 30, 2021 | 2.26 Mn |